CYP3A activity in European American and Japanese men using midazolam as an in vivo probe

Clinical Pharmacology and Therapeutics

Volumn 69, Issue 5, 2001, Pages 333-339

  Tateishi, Tomonori ^a,b,c,d   Watanabe, Minoru ^a,b,c,d   Nakura, Hironori ^a,b,c,d   Asoh, Masako ^a,b,c,d   Shirai, Hiroaki ^a,b,c,d   Mizorogi, Yoshihiro ^a,b,c,d   Kobayashi, Shinichi ^a,b,c,d   Thummel, Kenneth E ^a,b,c,d   Wilkinson, Grant R ^a,b,c,d  

^a ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Clinical Pharmacology Center   (Japan)

^c UNIVERSITY OF WASHINGTON   (United States)

^d VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 3A; DRUG METABOLITE; MIDAZOLAM; MIDAZOLAM MALEATE;

ADULT; ARTICLE; BODY COMPOSITION; BODY WEIGHT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISTRIBUTION VOLUME; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG HALF LIFE; DRUG METABOLISM; ENZYME ACTIVITY; ETHNOLOGY; HUMAN; HUMAN EXPERIMENT; JAPAN; MALE; NORMAL HUMAN; PRIORITY JOURNAL;

ADMINISTRATION, ORAL; ADULT; ARYL HYDROCARBON HYDROXYLASES; BIOLOGICAL AVAILABILITY; CYTOCHROME P-450 CYP3A; CYTOCHROME P-450 ENZYME SYSTEM; EUROPEAN CONTINENTAL ANCESTRY GROUP; GABA MODULATORS; HALF-LIFE; HUMANS; INJECTIONS, INTRAVENOUS; JAPAN; MALE; MIDAZOLAM; OXIDOREDUCTASES, N-DEMETHYLATING; TISSUE DISTRIBUTION;

EID: 0035338739     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1067/mcp.2001.115447     Document Type: Article

References (36)

1. Goldstein JA, Ishizaki T, Chiba K, deMorais SMF, Bell D, Krahn PM, Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and American black populations. Pharmacogenetics 1997;7:59-64.
2. Meyer UA, Zanger UM. Molecular mechanisms of genetic polymorphisms of drug metabolism. Annu Rev Pharmacol Toxicol 1997;37:269-96.
3. Nakamura K, Goto F, Ray WA, McAllister CB, Jacqz E, Wilkinson GR, Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations. Clin Pharmacol Ther 1985;38:402-8.
4. Bertilsson L, Lou Y-Q, Du Y-L, Liu Y, Kuang T-Y, Liao X-M, Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquin and S-mephenytoin. Clin Pharmacol Ther 1992;51:388-97.
5. Kim RB, Yamazaki H, Chiba K, O'Shea D, Mimura M, Guengerich FP, In vivo and in vitro characterization of CYP2E1 activity in Japanese and Caucasians. J Pharmacol Exp Ther 1996;279:4-11.
6. Castañeda-Hernandez G, Hoyo-Vadillo C, Palma-Aguirre JA, Flores-Murrieta FJ. Pharmacokinetics of oral nifedipine in different populations. J Clin Pharmacol 1993;33: 140-5.
7. Sowunmi A, Rashid TJ, Akinyinka OO, Renwick AG. Ethnic differences in nifedipine kinetics: Comparisons between Nigerians, Caucasians and South Asians. Br J Clin Pharmacol 1995;40:489-93.
8. Maurel P. The CYP3 family. In: Cytochromes P450: Metabolic and Toxicological Aspects. Ioannides C, editor. Boca Raton (FL): CRC Press; 1996. p. 241-70.
9. Thummel KE, Kunze KL, Shen DD. Enzyme-catalyzed processes of first-pass hepatic and intestinal drug extraction. Adv Drug Del Rev 1997;27:99-127.
10. Paine MF, Shen DD, Kunze KL, Perkins JD, Marsh CL, McVicar JP, First-pass metabolism of midazolam by the human intestine. Clin Pharmacol Ther 1996;60:14-24.
11. Lown KL, Kolars JC, Thummel KE, Barnett JL, Kunze KS, Wrighton SA, Interpatient heterogeneity in expression of CYP3A4 and CYP3A5 in small bowel - lack of prediction by the erythromycin breath test. Drug Metab Dispos 1994;22:947-55.
12. Thummel KE, O'Shea D, Paine MF, Shen DD, Kunze KL, Perkins JD, Oral first pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism. Clin Pharmacol Ther 1996;59:491-502.
13. Wandel C, Witte JS, Hall JM, Stein CM, Wood AJ, Wilkinson GR. CYP3A activity in African- and European-American men: Population differences and functional effect of the CYP3A4*1B 5′-promoter region polymorphism. Clin Pharmacol Ther 2000;68:82-91.
14. Kronbach T, Mathys D, Umeno M, Gonzalez FJ, Meyer UA. Oxidation of midazolam and triazolam by human liver cytochrome P450IIIA4. Mol Pharmacol 1989;36:89-96.
15. Gorski JC, Hall SD, Jones DR, VandenBraden M, Wrighton SA. Regioselective biotransformation of midazolam by members of the human cytochrome P4503A (CYP3A) subfamily. Biochem Pharmacol 1994;47:1643-53.
16. Kim RB, Wandel C, Leake B, Cvetkovic M, Fromm MF, Dempsey PJ, Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein. Pharm Res 1999;16:408-14.
17. Thummel KE, Shen DD, Podoll TD, Kunze KL, Trager WF, Hartwell PS, Use of midazolam as a human cytochrome P450 3A probe: I. In vitro-in vivo correlations in liver transplant patients. J Pharmacol Exp Ther 1994;271:549-56.
18. Thummel KE, Shen DD, Podoll TD, Kunze KL, Trager WF, Bacchi CE, Use of midazolam as a human cytochrome P450 3A probe; II: Characterization of inter- and intraindividual hepatic CYP3A variability after liver transplantation. J Pharmacol Exp Ther 1994;271:557-66.
19. Laub PB, Gallo JM. NCOMP - A windows-based computer program for noncompartmental analysis of pharmacokinetic data. J Pharm Sci 1996;85:393-5.
20. Gibaldi M, Perrier D. Pharmacokinetics. 2nd Ed. New York: Marcel Dekker; 1982.
21. Smith MT, Eadie MJ, Brophy TO. The pharmacokinetics of midazolam in man. Eur J Clin Pharmacol 1981;19:271-8.
22. Pirttiaho HI, Sotaniemi EA, Pelkonen RO, Pitkänen U. Hepatic blood flow and drug metabolism in patients on enzyme-inducing anticonvulsants. Eur J Clin Pharmacol 1982;22:441-5.
23. Wood AJ, Zhou HH. Ethnic differences in drug disposition and responsiveness. Clin Pharmacokinet 1991;20: 350-73.
24. Kumana CR, Lauder IJ, Chan M, Ko W, Lin HJ. Differences in diazepam pharmacokinetics in Chinese and White Caucasians - relation to body lipid stores. Eur J Clin Pharmacol 1987;32:211-5.
25. Lown KS, Bailey DG, Fontana RJ, Janardan SK, Adair CH, Fortlage LA, Grapefruit juice increases felodipine oral availability in humans by decreasing intestinal CYP3A protein expression. J Clin Invest 1997;99:2545-53.
26. Schmiedlin-Ren P, Ewards DJ, Fitzsimmons ME, He K, Lown KS, Woster PM, Mechanisms of enhanced oral availability of CYP3A4 substrates by grapefruit constituents - decreased enterocyte CYP3A4 concentration and mechanism-based inactivation by furanocoumarins. Drug Metab Dispos 1997;25:1228-33.
27. Balson KR, Morgan DJ, Richmond BH, McAlindon ME, Elliott SL, Yeomans ND. Pharmacokinetics of midazolam in Vietnamese subjects. J Gastroenterol Hepatol 1996;11:1177-80.
28. Mück W, Tanaka T, Ahr G, Kuhlmann J. No interethnic differences in stereoselective disposition of oral nimodipine between Caucasian and Japanese subjects. Int J Clin Pharmacol Ther 1996;34:163-71.
29. Tanaka T, Terashima S, Yoshikawa K, Schaefer HG, Ahr G, Matsuki T. Investigation on the interethnic differences in the pharmacokinetics of nifedipine and nisoldipine. Jpn J Clin Pharmacol Ther 1996;27:31-2.
30. Guengerich FP, Brian WR, Iwasaki M, Sari M-A, BäärnHielm C, Bernstsson P. Oxidation of dihydropyridine calcium channel blockers and analogues by human liver cytochrome P-450 IIIA4. J Med Chem 1991;34:1838-44.
31. Guengerich FP, Martin MV, Beaune PH, Kremers P, Wolff T, Waxman DJ. Characterization of rat and human liver microsomal cytochrome P-450 forms involved in nifedipine oxidation, a prototype for genetic polymorphism in oxidative drug metabolism. J Biol Chem 1986;261:5051-60.
32. Ahsan CH, Renwick AG, Waller DG, Challenor VF, George GF, Amanullah M. The influences of dose and ethnic origins on the pharmacokinetics of nifedipine. Clin Pharmacol Ther 1993;54:329-38.
33. Rashid TJ, Martin U, Clarke H, Waller DG, Renwick AG, George CF. Factors affecting the absolute bioavailability of nifedipine. Br J Clin Pharmacol 1995;40:51-8.
34. Castañeda-Hernández G, Palma-Aguirre JA, Montoya- Cabrera A, Flores-Murrieta FJ. Interethnic variability in nifedipine disposition: Reduced systemic plasma clearance in Mexican subjects [letter]. Br J Clin Pharmacol 1996;41:433-4.
35. Min DI, Lee M, Ku Y-M, Flanigan M. Gender-dependent racial difference in disposition of cyclosporine among healthy African American and white volunteers. Clin Pharmacol Ther 2000;68:478-86.
36. Mancinelli L, Frasseto L, Floren LC, Dressler D, Carrier S, Bekersky I, The pharmacokinetics and metabolic disposition of tacrolimus: A comparison across ethnic groups. Clin Pharmacol Ther 2001;69:24-31.